Department of Hematology and Oncological Sciences "L.A. Seragnoli", S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Cancer Treat Rev. 2010 Feb;36(1):63-8. doi: 10.1016/j.ctrv.2009.10.004. Epub 2009 Nov 14.
Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines the rationale for developing new combined therapeutic approaches, and describes the state of the art of the various potential strategies and the promising research perspectives.
在胃肠道间质瘤患者的治疗中，对酪氨酸激酶抑制剂的耐药性仍然是一个悬而未决的问题。在多耐药环境下疾病的复杂生物学特性导致人们越来越迫切地需要开发联合或整合治疗方法。这篇迷你综述概述了开发新的联合治疗方法的基本原理，并描述了各种潜在策略的最新技术状态和有前途的研究前景。
